Drug intelligence / Profile preview

SHD099

Development stage: Unknown
Lead developer: Shihuida Pharmaceutical Group

Overview

SHD099 is a biological drug candidate currently under development by Shihuida Pharmaceutical Group. It is specifically designed for the treatment of autoimmune diseases. While the specific molecular target and mechanism of action have not been publicly disclosed in detail, the drug is part of the company's biological pipeline and has progressed into Phase 2 clinical development. As a biologic, it likely functions by modulating specific components of the immune system to address underlying inflammatory or autoimmune pathologies.

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on SHD099.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHD099.

Explore the full profile